JQDN

General

Treatment Of Periocular Lentigo Maligna With Topical 5

Di: Stella

To evaluate the efficacy of topical imiquimod 5%, a local immune response modifier, in the treatment of periocular lentigo maligna. To evaluate the efficacy of topical imiquimod 5%, a local immune response modifier, in the treatment of periocular lentigo maligna. Powell, Topical imiquimod immunotherapy in the management of lentigo maligna, Clin Exp Dermatol, № 29, с. 15 https://doi.org/10.1111/j.1365-2230.2004.01452.x van Meurs, Recurrence

(PDF) Use of Imiquimod 5% cream for the treatment of lentigo maligna on ...

Here we review the reported literature about the use of Imiquimod 5% topical cream for lentigo maligna of the eyelid, the treatment outcomes, side effects and tolerance.

Topical 5% imiquimod cream is an effective option as primary or adjunct therapy in the treatment of periocular melanoma in situ and Histologic clearance of atypical melanocytes on post

Successful Treatment of Lower Eyelid Melanoma in Situ

Abstract Topical imiquimod has been used off-label as monotherapy or adjuvant treatment for lentigo maligna. Our aim is to describe treatment modalities, clinical outcomes,

Abstract Topical imiquimod has been used off-label as monotherapy or adjuvant treatment for lentigo maligna. Our aim is to describe treatment modalities, clinical outcomes, Abstract Purpose: To evaluate the efficacy of topical 5% imiquimod cream in the treatment of periocular melanoma in situ (lentigo maligna). Design: Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature

Periocular lentigo maligna was treated with topical imiquimod 5%. The clinical features, treatment schedule, response to treatment, and complications were analyzed Periocular lentigo maligna was treated with topical imiquimod 5%. The clinical features, treatment schedule, response to treatment, and complications were analyzed retrospectively.

There was no recurrence of lentigo maligna in those with complete or partial response (mean follow-up, 20 months).Periocular lentigo maligna seems to respond to topical imiquimod 5%

Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment

Topical imiquimod may be a therapeutic option for the treatment of melanoma in situ and lentigo maligna melanoma due to its efficacy, tolerability, and non-invasiveness. The purpose of this systematic review is to assemble current Therefore, considering the benefits of IMQ and the absence of permanent ocular side effects, the use of IMQ in the periocular area should not be avoided for fear of conjunctival inflammation To the Editor Lentigo maligna (LM) represents the most common subtype of melanoma in the elderly, affecting predominantly the head and neck region in photodamaged

Based on the data suggesting a good response of LM to topical treatment with IMQ 5%, it was started five days per week. Considering the tumor closeness to conjunctiva and cornea and the Methods Periocular lentigo maligna was treated with topical imiquimod 5%. The clinical features, treatment schedule, response to treatment, and complications were analyzed

Abstract Topical imiquimod 5% cream has been used successfully to treat eyelid basal cell carcinoma, Bowen’s disease of the eyelid and eyelid lentigo maligna. We report a The authors conclude that while periocular lentigo maligna seems to respond to topical imiquimod 5% cream, further study is needed. Subjects in the study were five

Lentigo Maligna Managed with Topical Imiquimod and Dermoscop ...

Three patients (5.3%) showed no response and another 3 patients (5.3%) stopped treatment due to side-effects. After 4.5 years during follow-up one patient developed a lentigo There was no recurrence of lentigo maligna in those with complete or partial response (mean follow-up, 20 months).CONCLUSIONS: Periocular lentigo maligna seems to respond to topical

Management of Eyelid Lentigo Maligna

Clinical usefulness of dermoscopy in the management of lentigo maligna melanoma treated with topical Mayara Hamilko de Barros, Claudio Conforti, Roberta Giuffrida, Fernanda Cristina

The common clinical subtypes of superficial spreading melanoma, nodular melanoma, and lentigo maligna melanoma occur on the eyelid, as in other cutaneous areas. Methods: Periocular lentigo maligna was treated with topical imiquimod 5%. The clinical features, treatment and complications were schedule, response to treatment, and complications were analyzed retrospectively. Lentigo maligna (LM) usually occurs in older individuals, with a peak incidence between 65 and 80 years [4,5]. The incidence of LM appears to be increasing in younger age

Reviewing Challenges in the Diagnosis and Treatment of Lentigo Maligna and Lentigo-Maligna Melanoma. Multifocal amelanotic conjunctival melanoma and acquired Periocular 14 Jul 2022 4 lentigo maligna was treated with topical imiquimod 5%. The clinical features, treatment schedule, response to treatment, and complications were analyzed

In the period 2007-2017 57 patients with lentigo maligna were treated with off-label topical imiquimod once daily for 12 weeks. Complete clinical clearance was observed in 48 Treatment of periocular lentigo maligna with topical 5% Imiquimod: a review. Neumann I, Patalay R, Kaushik M, Timlin H, Daniel C Eye (Lond), 37 (3):408-414, 14 Jul 2022 4. Use of interferon alpha 2b to manage conjunctival primary acquired melanosis and conjunctival melanoma;Survey of Ophthalmology;2022-09 5. Treatment of periocular lentigo maligna with

Periocular lentigo maligna was treated with topical imiquimod 5%. The clinical features, treatment schedule, response to treatment, and complications were analyzed “For this reason, it takes a particularly motivated patient to successfully complete treatment with Exp Dermatol 29 с topical imiquimod. However, once the area heals, more than 70 percent of PDF | On Nov 25, 2020, Marcos Oro‐Ayude and others published Periocular lentigo maligna successfully treated with immunocryosurgery | Find, read and cite all the research you need on

Download Citation | Combination Topical Therapy for Conjunctival Primary Acquired Melanosis With Atypia and Periocular Lentigo Maligna | Purpose: To report the case

Miss Claire Daniel : Ophthalmology

To evaluate the efficacy of topical imiquimod 5%, a local immune response modifier, in the treatment of periocular lentigo maligna.